Swiss neuroscientists have found a way to stop unwanted electrical noise in the brain while precisely targeting deep neural circuits for treatment—using a third electrode pair that acts as a silencer.
The breakthrough, published in Cell Systems by researchers at the University of Geneva's Synapsy Center for Neuroscience and Mental Health Research in collaboration with ETH Zurich, addresses a longstanding medical puzzle: how to reach deep brain structures that drive conditions like Parkinson's disease and depression without resorting to invasive surgery. Current options have always forced doctors to choose between precision and safety. Noninvasive techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) work from the scalp but only reach the brain's surface layers. Deep brain stimulation (DBS) reaches deeper structures effectively but demands surgical implantation of electrodes directly into the brain. A middle path called temporal interference stimulation (TIS) has promised noninvasive access to deep regions, but scientists hadn't fully understood the collateral damage it causes.
The Geneva team, led by Valerio Zerbi, an assistant professor in the departments of psychiatry and basic neuroscience at UNIGE's Faculty of Medicine, decided to measure exactly what TIS does across the entire brain. They stimulated the medial prefrontal cortex in mice using a combination of electrophysiology, calcium imaging, and functional MRI—creating a detailed map of where electrical activity spread beyond the target. What they found was sobering: while TIS did modulate neuronal activity in the intended region, it also triggered unwanted activations in other circuits throughout the brain.
"Thanks to functional MRI, we were able to visualize all the activated regions and quantify the off-target effects," Zerbi explains. That knowledge became the foundation for their innovation. Rather than abandon the approach, the researchers added a third pair of electrodes designed to generate a cancellation electric field. This field actively neutralizes the stimulation in nontargeted regions while preserving the therapeutic effect where it's needed most.
The principle rests on how neurons actually respond to electrical signals. High-frequency electric fields alone don't trigger neuronal activity effectively, but when two high-frequency fields with a slight frequency offset meet in the brain, their interference creates a slower signal that neurons can detect and respond to. By introducing a carefully calibrated cancellation field, the team could suppress that interference precisely where it wasn't wanted.
"The principle is not to stimulate the entire brain, but to target a specific network whose activity is disrupted," Zerbi says. For decades, that ideal remained out of reach. Many regions essential for movement, memory, and emotional regulation sit deep in the brain, buried beneath layers of tissue that surface-level stimulation cannot penetrate without damaging the overlying structures.
This refinement matters because it opens a safer path to treating neurological and psychiatric conditions that demand precision. Parkinson's disease, depression, obsessive-compulsive disorder, and treatment-resistant epilepsy all involve specific circuits buried in the brain's depths. If the third electrode pair proves effective in human trials—something the Geneva team's mouse experiments suggest is plausible—patients could access targeted brain stimulation without the risks and recovery time surgery demands. The work represents a step toward bringing a powerful tool from the laboratory into clinics, where it could change how neurologists approach disorders once considered untreatable without invasive intervention.